Arcellx (ACLX) Competitors

Genmab A/S (NASDAQ:GMAB) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Which has higher valuation & earnings, GMAB or ACLX?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	5.76	$631.91M	$1.03	20.19
Arcellx	$110.32M	32.59	-$70.69M	-$0.71	-93.63

Does the media favor GMAB or ACLX?

In the previous week, Genmab A/S had 1 more articles in the media than Arcellx. MarketBeat recorded 7 mentions for Genmab A/S and 6 mentions for Arcellx. Genmab A/S's average media sentiment score of 0.96 beat Arcellx's score of 0.32 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcellx	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in GMAB or ACLX?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 6.2% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Do analysts recommend GMAB or ACLX?

Genmab A/S currently has a consensus target price of $45.20, indicating a potential upside of 117.31%. Arcellx has a consensus target price of $105.93, indicating a potential upside of 59.34%. Given Genmab A/S's higher possible upside, research analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arcellx	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.13

Does the MarketBeat Community favor GMAB or ACLX?

Genmab A/S received 93 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Arcellx	Outperform Votes 68 82.93%	Underperform Votes 14 17.07%

Which has more volatility & risk, GMAB or ACLX?

Genmab A/S has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Is GMAB or ACLX more profitable?

Genmab A/S has a net margin of 23.49% compared to Arcellx's net margin of -25.94%. Genmab A/S's return on equity of 14.64% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Arcellx	-25.94%	-8.28%	-5.21%

Summary

Genmab A/S beats Arcellx on 12 of the 19 factors compared between the two stocks.